JB Pharma records revenue growth of 36 per cent to Rs 809 crore in Q2 FY23
Operating EBITDA grew by 44 per cent to Rs 202 crore
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
financial highlights
Lupin announces Q2 FY2023 results
India formulation sales for Q2 FY2023 were Rs 15,841 mn, up 6.2 per cent as compared to Rs 14,920 mn in Q1 FY2023
Piramal Pharma announces consolidated results for Q2 and H1 FY2023
Revenue from operation grew by 11 per cent to Rs 3,202 crore versus Rs 2,889 crore in H1FY22
Balaxi Pharma reports 23 per cent growth YoY during Q2FY23
Pharma revenue up 50 per cent with expanding contribution from Latin America
Eris Lifesciences’s Q2FY23 revenue up 28 per cent YoY
EBITDA at Rs 1,514 million, with 32.9 per cent EBITDA margin; PAT stood at Rs 1,194 million, with 25.9 per cent PAT margin
Hester Biosciences reports net profit of Rs 3.56 crore in Q1FY23
Sales of health products grew by 42 per cent on back of a strong momentum gained from new product introductions and territorial…
Lincoln Pharma reports standalone net profit of Rs 15.01 crore in Q1FY23
Total income in Q1FY23 at Rs 129.97 crore, up 24.4 per cent from Rs 104.4 crore in Q4FY22
Balaxi Pharma revenue grows 42 per cent in Q1 FY23
Profit After Tax (PAT) up 32 per cent YoY
Torrent Pharma Q1 net profit up 2.8 per cent to Rs 330 crores
The company had posted a net profit of Rs 321 crores for the corresponding period of the previous fiscal
Granules India reports income from operations at Rs 1,030 crores up 29 per cent
YoY, EBITDA at Rs 193 crores, EBITDA margin at 19 per cent; PAT at Rs 111 crores